O	0	6	Twenty
O	6	7	-
O	7	11	year
O	12	18	follow
O	18	19	-
O	19	21	up
O	22	24	of
O	25	26	a
O	27	37	randomized
O	38	43	study
O	44	53	comparing
B-intervention	54	60	breast
I-intervention	60	61	-
I-intervention	61	71	conserving
I-intervention	72	79	surgery
O	80	84	with
B-control	85	92	radical
I-control	93	103	mastectomy
O	104	107	for
O	108	113	early
O	114	120	breast
O	121	127	cancer
O	127	128	.

O	129	131	We
O	132	141	conducted
O	142	144	20
O	145	150	years
O	151	153	of
O	154	160	follow
O	160	161	-
O	161	163	up
O	164	166	of
O	167	172	women
O	173	181	enrolled
O	182	184	in
O	185	186	a
O	187	197	randomized
O	198	203	trial
O	204	206	to
O	207	214	compare
O	215	218	the
O	219	227	efficacy
O	228	230	of
O	231	238	radical
O	239	240	(
O	240	247	Halsted
O	247	248	)
O	249	259	mastectomy
O	260	264	with
O	265	269	that
O	270	272	of
O	273	279	breast
O	279	280	-
O	280	290	conserving
O	291	298	surgery
O	298	299	.

O	300	304	From
O	305	309	1973
O	310	312	to
O	313	317	1980
O	317	318	,
B-total-participants	319	322	701
B-eligibility	323	328	women
I-eligibility	329	333	with
I-eligibility	334	340	breast
I-eligibility	341	348	cancers
I-eligibility	349	358	measuring
I-eligibility	359	361	no
I-eligibility	362	366	more
I-eligibility	367	371	than
I-eligibility	372	373	2
I-eligibility	374	376	cm
O	377	379	in
O	380	388	diameter
O	389	393	were
O	394	402	randomly
O	403	411	assigned
O	412	414	to
O	415	422	undergo
O	423	430	radical
O	431	441	mastectomy
O	442	443	(
B-control-participants	443	446	349
O	447	455	patients
O	455	456	)
O	457	459	or
O	460	466	breast
O	466	467	-
O	467	477	conserving
O	478	485	surgery
O	486	487	(
O	487	501	quadrantectomy
O	501	502	)
O	503	511	followed
O	512	514	by
O	515	527	radiotherapy
O	528	530	to
O	531	534	the
O	535	546	ipsilateral
O	547	554	mammary
O	555	561	tissue
O	562	563	(
B-intervention-participants	563	566	352
O	567	575	patients
O	575	576	)
O	576	577	.

O	578	583	After
O	584	588	1976
O	588	589	,
O	590	598	patients
O	599	601	in
O	602	606	both
O	607	613	groups
O	614	617	who
O	618	621	had
O	622	630	positive
O	631	639	axillary
O	640	645	nodes
O	646	650	also
O	651	659	received
O	660	668	adjuvant
O	669	681	chemotherapy
O	682	686	with
O	687	703	cyclophosphamide
O	703	704	,
O	705	717	methotrexate
O	717	718	,
O	719	722	and
O	723	735	fluorouracil
O	735	736	.

B-iv-bin-abs	737	743	Thirty
O	744	749	women
O	750	752	in
O	753	756	the
O	757	762	group
O	763	767	that
O	768	777	underwent
O	778	784	breast
O	784	785	-
O	785	795	conserving
O	796	803	therapy
O	804	807	had
O	808	809	a
B-outcome	810	820	recurrence
I-outcome	821	823	of
I-outcome	824	829	tumor
O	830	832	in
O	833	836	the
O	837	841	same
O	842	848	breast
O	848	849	,
O	850	857	whereas
B-cv-bin-abs	858	863	eight
O	864	869	women
O	870	872	in
O	873	876	the
O	877	884	radical
O	884	885	-
O	885	895	mastectomy
O	896	901	group
O	902	905	had
O	906	911	local
O	912	923	recurrences
O	924	925	(
O	925	926	P
O	926	927	<
O	927	928	0
O	928	929	.
O	929	932	001
O	932	933	)
O	933	934	.

O	935	938	The
O	939	944	crude
B-outcome	945	955	cumulative
I-outcome	956	965	incidence
O	966	968	of
O	969	974	these
O	975	981	events
O	982	985	was
B-iv-bin-percent	986	987	8
I-iv-bin-percent	987	988	.
I-iv-bin-percent	988	989	8
I-iv-bin-percent	990	997	percent
O	998	1001	and
B-cv-bin-percent	1002	1003	2
I-cv-bin-percent	1003	1004	.
I-cv-bin-percent	1004	1005	3
I-cv-bin-percent	1006	1013	percent
O	1013	1014	,
O	1015	1027	respectively
O	1027	1028	,
O	1029	1034	after
O	1035	1037	20
O	1038	1043	years
O	1043	1044	.

O	1045	1047	In
O	1048	1056	contrast
O	1056	1057	,
O	1058	1063	there
O	1064	1067	was
O	1068	1070	no
O	1071	1082	significant
O	1083	1093	difference
O	1094	1101	between
O	1102	1105	the
O	1106	1109	two
O	1110	1116	groups
O	1117	1119	in
O	1120	1123	the
B-outcome	1124	1129	rates
I-outcome	1130	1132	of
I-outcome	1133	1146	contralateral
I-outcome	1146	1147	-
I-outcome	1147	1153	breast
I-outcome	1154	1164	carcinomas
O	1164	1165	,
B-outcome	1166	1173	distant
I-outcome	1174	1184	metastases
O	1184	1185	,
O	1186	1188	or
B-outcome	1189	1195	second
I-outcome	1196	1203	primary
I-outcome	1204	1211	cancers
O	1211	1212	.

O	1213	1218	After
O	1219	1220	a
O	1221	1227	median
O	1228	1234	follow
O	1234	1235	-
O	1235	1237	up
O	1238	1240	of
O	1241	1243	20
O	1244	1249	years
O	1249	1250	,
O	1251	1254	the
O	1255	1259	rate
O	1260	1262	of
B-outcome	1263	1268	death
I-outcome	1269	1273	from
I-outcome	1274	1277	all
I-outcome	1278	1284	causes
O	1285	1288	was
B-iv-bin-percent	1289	1291	41
I-iv-bin-percent	1291	1292	.
I-iv-bin-percent	1292	1293	7
I-iv-bin-percent	1294	1301	percent
O	1302	1304	in
O	1305	1308	the
O	1309	1314	group
O	1315	1319	that
O	1320	1329	underwent
O	1330	1336	breast
O	1336	1337	-
O	1337	1347	conserving
O	1348	1355	surgery
O	1356	1359	and
B-cv-bin-percent	1360	1362	41
I-cv-bin-percent	1362	1363	.
I-cv-bin-percent	1363	1364	2
I-cv-bin-percent	1365	1372	percent
O	1373	1375	in
O	1376	1379	the
O	1380	1387	radical
O	1387	1388	-
O	1388	1398	mastectomy
O	1399	1404	group
O	1405	1406	(
O	1406	1407	P
O	1407	1408	=
O	1408	1409	1
O	1409	1410	.
O	1410	1411	0
O	1411	1412	)
O	1412	1413	.

O	1414	1417	The
O	1418	1428	respective
O	1429	1434	rates
O	1435	1437	of
B-outcome	1438	1443	death
I-outcome	1444	1448	from
I-outcome	1449	1455	breast
I-outcome	1456	1462	cancer
O	1463	1467	were
B-iv-bin-percent	1468	1470	26
I-iv-bin-percent	1470	1471	.
I-iv-bin-percent	1471	1472	1
I-iv-bin-percent	1473	1480	percent
O	1481	1484	and
B-cv-bin-percent	1485	1487	24
I-cv-bin-percent	1487	1488	.
I-cv-bin-percent	1488	1489	3
I-cv-bin-percent	1490	1497	percent
O	1498	1499	(
O	1499	1500	P
O	1500	1501	=
O	1501	1502	0
O	1502	1503	.
O	1503	1504	8
O	1504	1505	)
O	1505	1506	.

O	1507	1510	The
B-outcome	1511	1515	long
I-outcome	1515	1516	-
I-outcome	1516	1520	term
I-outcome	1521	1529	survival
I-outcome	1530	1534	rate
O	1535	1540	among
O	1541	1546	women
O	1547	1550	who
O	1551	1558	undergo
O	1559	1565	breast
O	1565	1566	-
O	1566	1576	conserving
O	1577	1584	surgery
O	1585	1587	is
O	1588	1591	the
O	1592	1596	same
O	1597	1599	as
O	1600	1604	that
O	1605	1610	among
O	1611	1616	women
O	1617	1620	who
O	1621	1628	undergo
O	1629	1636	radical
O	1637	1647	mastectomy
O	1647	1648	.

O	1649	1655	Breast
O	1655	1656	-
O	1656	1666	conserving
O	1667	1674	surgery
O	1675	1677	is
O	1678	1687	therefore
O	1688	1691	the
O	1692	1701	treatment
O	1702	1704	of
O	1705	1711	choice
O	1712	1715	for
O	1716	1721	women
O	1722	1726	with
O	1727	1737	relatively
O	1738	1743	small
O	1744	1750	breast
O	1751	1758	cancers
O	1758	1759	.
